TW202334219A - 抗ｃｄ１２２抗體、抗ｃｄ１３２抗體及相關的雙特異性結合蛋白 - Google Patents

抗ｃｄ１２２抗體、抗ｃｄ１３２抗體及相關的雙特異性結合蛋白 Download PDF

Info

Publication number
TW202334219A
TW202334219A TW111141612A TW111141612A TW202334219A TW 202334219 A TW202334219 A TW 202334219A TW 111141612 A TW111141612 A TW 111141612A TW 111141612 A TW111141612 A TW 111141612A TW 202334219 A TW202334219 A TW 202334219A
Authority
TW
Taiwan
Prior art keywords
seq
cdr
sequence
antibody
antigen
Prior art date
Application number
TW111141612A
Other languages
English (en)
Chinese (zh)
Inventor
宮世勇
黃莉妮
辰冰 吳
吳丹青
巫玄
張瑞
Original Assignee
香港商岸邁生物科技（香港）有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 香港商岸邁生物科技（香港）有限公司 filed Critical 香港商岸邁生物科技（香港）有限公司
Publication of TW202334219A publication Critical patent/TW202334219A/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/66—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a swap of domains, e.g. CH3-CH2, VH-CL or VL-CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
TW111141612A 2021-11-02 2022-11-01 抗ｃｄ１２２抗體、抗ｃｄ１３２抗體及相關的雙特異性結合蛋白 TW202334219A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
WOPCT/CN2021/128208 2021-11-02
CN2021128208 2021-11-02
WOPCT/CN2022/127036 2022-10-24
PCT/CN2022/127036 WO2023078113A1 (en) 2021-11-02 2022-10-24 Anti-cd122 antibodies, anti-cd132 antibodies, and related bispecific binding proteins

Publications (1)

Publication Number Publication Date
TW202334219A true TW202334219A (zh) 2023-09-01

Family

ID=86240641

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111141612A TW202334219A (zh) 2021-11-02 2022-11-01 抗ｃｄ１２２抗體、抗ｃｄ１３２抗體及相關的雙特異性結合蛋白

Country Status (7)

Country Link
US (1) US20250002594A1 (https=)
EP (1) EP4426742A4 (https=)
JP (1) JP2024541048A (https=)
CN (1) CN118251416A (https=)
CA (1) CA3236138A1 (https=)
TW (1) TW202334219A (https=)
WO (1) WO2023078113A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
US12311033B2 (en) 2023-05-31 2025-05-27 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
CN116789828B (zh) * 2023-05-31 2023-11-17 中国医学科学院皮肤病医院(中国医学科学院皮肤病研究所) 一种抗cd132的单克隆抗体及其应用
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
WO2025076127A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
CN117886940B (zh) * 2024-01-19 2024-11-19 中国医学科学院皮肤病医院(中国医学科学院皮肤病研究所) 人源化抗人cd132单克隆抗体及其应用
WO2025179294A2 (en) 2024-02-22 2025-08-28 Capstan Therapeutics, Inc. Immune engineering amplification
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2026033139A1 (en) 2024-08-09 2026-02-12 Twain Therapeutics Pte. Ltd. Antigen-binding molecules

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011127324A2 (en) * 2010-04-08 2011-10-13 JN Biosciences, LLC Antibodies to cd122
BR112016015140A2 (pt) * 2013-12-30 2018-01-23 Epimab Biotherapeutics Inc. imunoglobulina com fabs in-tandem e usos das mesmas
PT3328894T (pt) * 2015-08-06 2019-02-13 Agency Science Tech & Res Anticorpos de cadeia comum gama/il2rbeta
CN111954680B (zh) * 2017-11-10 2024-03-15 新加坡科技研究局 IL2Rβ/共同γ链抗体
TW202031683A (zh) * 2018-11-09 2020-09-01 新加坡商優其洛伊生物私人有限公司 介白素2受體β(IL2Rβ)/共同γ鏈抗體
MX2021008958A (es) * 2019-02-01 2021-11-04 Regeneron Pharma Proteínas de unión a antígeno del receptor gamma anti-il2.

Also Published As

Publication number Publication date
JP2024541048A (ja) 2024-11-06
US20250002594A1 (en) 2025-01-02
CN118251416A (zh) 2024-06-25
CA3236138A1 (en) 2023-05-11
WO2023078113A1 (en) 2023-05-11
EP4426742A1 (en) 2024-09-11
EP4426742A4 (en) 2025-12-24

Similar Documents

Publication Publication Date Title
US20250002594A1 (en) Anti-cd122 antibodies, anti-cd132 antibodies, and related bispecific binding proteins
JP7562528B2 (ja) 抗体及びその用途
CN113480656B (zh) 抗ror1抗体
CN110407941B (zh) Cd39的高亲和力抗体及其用途
JP2022024054A (ja) 細胞傷害性ｔリンパ球関連タンパク質４（ｃｔｌａ－４）に対する新規モノクローナル抗体
CN114728065A (zh) 针对cd3和bcma的抗体和自其制备的双特异性结合蛋白
US20240425593A1 (en) Anti-pd-1 antibody and use thereof
KR20220137723A (ko) 항-cd3 및 항-cd123 이중 특이성 항체 및 이의 용도
WO2022258015A1 (en) Antibodies and bispecific binding proteins that bind ox40 and/or pd-l1
US20240317862A1 (en) Anti-b7-h3 monoclonal antibody and use thereof
EP4613767A1 (en) Bispecific antibody for glypican-3 and use thereof
RU2844869C1 (ru) Антитела против ror1 и родственные биспецифичные связывающие белки
HK40061499A (en) Anti-ror1 antibodies
KR20240046557A (ko) 항-b7-h4 항체 및 이의 제조 방법과 용도
HK40067877A (en) Antibodies to cd3 and bcma, and bispecific binding proteins made therefrom
TW202509067A (zh) 抗ｃｄ２５抗體及其用途
HK40016809B (en) High affinity antibodies to cd39 and uses thereof
HK40016809A (en) High affinity antibodies to cd39 and uses thereof